XSTO
COMBI
Market cap5mUSD
May 02, Last price
2.59SEK
1D
-1.52%
1Q
12.61%
Jan 2017
-93.82%
IPO
-97.54%
Name
Combigene AB
Chart & Performance
P/E
—
P/S
157.32
EPS
—
Div Yield, %
—
Shrs. gr., 5y
46.15%
Rev. gr., 5y
-53.49%
Revenues
326k
-94.12%
Net income
-45m
L+25.83%
CFO
-30m
L-1.99%
Earnings
May 23, 2025
Profile
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | 326 -94.12% | 5,544 -79.23% | 26,699 -68.23% | |||||||
Cost of revenue | 26,835 | 45,900 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 326 | (21,291) | (19,200) | |||||||
NOPBT Margin | 100.00% | |||||||||
Operating Taxes | (790) | |||||||||
Tax Rate | ||||||||||
NOPAT | 326 | (21,291) | (18,410) | |||||||
Net income | (44,878) 25.83% | (35,665) 564.56% | (5,367) -125.60% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (73,748) | (101,445) | (131,777) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (29,949) | (30,557) | (16,666) | |||||||
CAPEX | (109) | |||||||||
Cash from investing activities | (81) | (989) | ||||||||
Cash from financing activities | ||||||||||
FCF | 502 | (20,800) | (19,751) | |||||||
| Balance | ||||||||||
Cash | 73,748 | 101,440 | 131,777 | |||||||
Long term investments | 5 | |||||||||
Excess cash | 73,732 | 101,168 | 130,442 | |||||||
Stockholders' equity | (43,888) | (107,667) | (72,002) | |||||||
Invested Capital | 115,467 | 224,124 | 224,047 | |||||||
ROIC | 0.19% | |||||||||
ROCE | 0.46% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 19,801 | 19,801 | 19,801 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 326 | (20,961) | (16,606) | |||||||
EV/EBITDA | ||||||||||
Interest | 5 | 2 | ||||||||
Interest/NOPBT | ||||||||||